Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cardiome -- CRME -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (32)	7/24/2006 9:34:43 AM
From: dr.praveen	Read Replies (2) \| Respond to of 285

Thanks Tuck...! I doubled my position after my initial loss when the RTF letter came for the IV dose. I am planning to buy more on dips and it is not late at all for you since it is trading at the level before the RTF letter came and there will be dips in the future. "Enrollment and dosing for the second stage of this study, evaluating patients receiving a 600mg dose of RSD1235 (oral) or placebo twice per day, has now been completed. Results from this dosing group, and the complete study, are expected later in the 3rd quarter of this year." Regards, Praveen